NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Cigna Corp. (NYSE: CI), Medtronic, Inc. (NYSE: MDT), WellPoint Inc. (NYSE: WLP), Mylan, Inc. (NASDAQ: MYL), and Express Scripts Inc. (NASDAQ: ESRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Cigna Corp. Analyst Notes
On March 28, 2014, Cigna Corp. (Cigna) announced that via its award-winning Colorectal Cancer Screening Program, the Company intends to reach two million people in 2014 that are due for screening through a combination of targeted online messages and direct mail. According to the Company, approximately 280,000 newly eligible individuals covered by a Cigna medical plan, between the ages of 50 and 64, and whose claims data indicate they have not had a colorectal cancer screening, will receive information in the mail about appropriate colon cancer screening tests, including colonoscopy. Scott Josephs, M.D., Cigna National Medical Officer, stated, "Colorectal cancer is treatable and preventable, especially if detected early, which is why educating customers about screening is so important. We saw a significant increase in the rate of screenings as a result of last year's campaign, and we want that trend to continue in 2014 and beyond." The full analyst notes on Cigna Corp. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/CI/report.pdf
--
Medtronic, Inc. Analyst Notes
On March 31, 2014, Medtronic, Inc. (Medtronic) announced the final follow-up results from the CoreValve® CE Pivotal Study, which demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who were treated with the self-expanding CoveValve System. According to Medtronic, the study results showed the long-term durability and excellent clinical performance of the CoreValve System with no incidences of structural valve dysfunction at four years. The Company stated that the study also showed significant improvements in quality of life at one year, which were sustained through four years. Rhonda Robb, Vice President and General Manager of Catheter Based Therapies at Medtronic, stated, "We are very encouraged by these long-term durability results for the CoreValve System, which supplement the exceptional clinical outcomes demonstrated through the U.S. pivotal trial. For patients needing a less invasive approach for aortic valve replacement, this therapy is showing great promise with high survival rates, low stroke rates and now reliable durability out to four years." The full analyst notes on Medtronic, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/MDT/report.pdf
--
WellPoint Inc. Analyst Notes
On March 27, 2014, WellPoint Inc. (WellPoint) announced that it will release its Q1 2014 financial results on April 30, 2014, at 6:00 a.m. EDT. According to the Company, management will review the results and its outlook during a conference call on the same day at 8:30 a.m. EDT. Additionally, the WellPoint stated that replay of the conference call will be available from 11:00 a.m. EDT on April 30, 2014 until the end of the day on May 14, 2014. The full analyst notes on WellPoint Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/WLP/report.pdf
--
Mylan, Inc. Analyst Notes
On March 27, 2014, Mylan, Inc. (Mylan) announced that after a trial in the United States District Court for the District of New Jersey, a jury returned a verdict in favor of the Company in its breach of contract lawsuit against GlaxoSmithKline (GSK) relating to Paroxetine Hydrochloride Extended-release (ER) Tablets. According to the Company, the jury has decided that GSK owes Mylan $106.7 million in damages. Additionally, the Company stated that its claims were based on 2007 agreements with GSK relating to Mylan's Abbreviated New Drug Application (ANDA) for Paroxetine Hydrochloride ER Tablets pursuant to which, Mylan obtained certain intellectual property rights from GSK. Mylan informed that it then launched its generic Paroxetine Hydrochloride ER Tablets in May 2008 and, is the only company to have received FDA approval of an ANDA for this product, to date. The full analyst notes on Mylan, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/MYL/report.pdf
--
Express Scripts Inc. Analyst Notes
On March 20, 2014, Express Scripts Inc. (Express Scripts) announced that the Ethisphere Institute has recognized the Company as a 2014 World's Most Ethical Company®. The Company informed that the aforesaid award recognizes organizations that continue to raise the bar on ethical leadership and corporate behavior. Additionally, the Company stated that it is the one of only eight companies in the healthcare services industry and the only pharmacy benefit manager to receive the honor in 2014. Christine Wiehl, Vice President and Chief Compliance Officer at Express Scripts, stated, "Tens of millions of people trust Express Scripts to manage their pharmacy benefit, and we work to earn that trust with an unwavering commitment to ethical behavior, good governance and alignment to the best interests of clients and patients. While we are proud to be honored by Ethisphere, we are even prouder of what we do every day to help make the use of prescription drugs safer and more affordable." The full analyst notes on Express Scripts Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/ESRX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
